HTB South

Treatment access

FDA approval of generic ARVs

Global Fund reports rise in people on treatment

TRIPS agreement flexibilities provide opportunities for improved access to ARVs

Driving a decade of change: HIV/AIDS, patents and access to medicines for all

Virological findings from the SARA trial of boosted protease inhibitor monotherapy

FDA approval of generic ARVs

ART distribution and adherence support by community groups in Mozambique

First-line ART outcomes: Trial finds nurses non-inferior to doctors

Cotrimoxazole prophylaxis reduces mortality in patients on ART with low CD4 counts or WHO stage 3 and 4 disease

FDA approval of generic ARVs

Waiting lists grow in the US

MSF criticise Abbott over new ritonavir formulation

More concerning research on the Free State ART programme

FDA approval of generic ARVs

PEPFAR launches five-year strategy

Global Fund approves US$2.4 billion in new grants

UNITAID decision to fund ‘patent pool’ to boost access to new medicines

Factors affecting cost of ART: Data from Aid for AIDS

AIDS and mortality in South Africa

FDA approval of generic ARVs

Punishing success in tackling AIDS: funders’ retreat could wipe out health gains in HIV affected countries

Update on unmet need for HAART in South Africa

ARV Programme results reports at IAS

Guidelines on when to start treatment in resource poor settings

AIDS medicine prices in the South African public and private sectors

TMC207 open label trial for MDR-TB

FDA approval of generic ARVs

FDA approval of generic ARVs

HIV medicine prices in the South African private sector

FDA approval of generic drugs

Lost benefit of ARVs in South Africa

FDA approval of generic ARVs

Atripla to be licensed in Latin America and the Asia-Pacific region

Post navigation